Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Raised by Sigma Planning Corp

Sigma Planning Corp grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 409 shares of the biopharmaceutical company’s stock after purchasing an additional 16 shares during the quarter. Sigma Planning Corp’s holdings in Regeneron Pharmaceuticals were worth $430,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of REGN. International Assets Investment Management LLC boosted its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Capital International Investors grew its holdings in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares during the period. Swedbank AB acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $129,257,000. Finally, Epoch Investment Partners Inc. bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $99,667,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $756.81 on Friday. The company has a market capitalization of $83.17 billion, a PE ratio of 18.73, a PEG ratio of 3.04 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company’s 50 day moving average price is $992.70 and its 200 day moving average price is $1,033.92. Regeneron Pharmaceuticals, Inc. has a 52 week low of $753.69 and a 52 week high of $1,211.20.

Analyst Ratings Changes

Several research analysts have recently issued reports on REGN shares. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Citigroup assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday. They issued a “neutral” rating and a $895.00 target price for the company. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday. They issued an “outperform” rating and a $1,150.00 price target for the company. Finally, Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.